NCT05914506View on ClinicalTrials.gov

Hyperpolarized 129-Xenon MRI in Fibrosing Interstitial Lung Disease

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

October 5, 2023

Primary Completion Date

May 1, 2028

Study Completion Date

May 1, 2028

Conditions
Progressive Fibrosing Interstitial Lung Disease
Interventions
DIAGNOSTIC_TEST

Hyperpolarized xenon-129 MRI

Participants will be asked to inhale the xenon-129 contrast agent according to procedure for gas administration. The success criterion of the drug is a obtained Xe MRI lung image with reasonable signal level

Trial Locations (1)

8200

RECRUITING

Aarhus University, Department of Clinical Medicine, MR Research Centre, Aarhus

All Listed Sponsors
collaborator

Aarhus University Hospital

OTHER

lead

University of Aarhus

OTHER